Premium
Hirudin and Hirulog
Author(s) -
White Harvey
Publication year - 1993
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1993.tb04761.x
Subject(s) - medicine , hirudin , streptokinase , tissue plasminogen activator , thrombin , heparin , discovery and development of direct thrombin inhibitors , thrombolysis , cardiology , myocardial infarction , platelet
A brief outline is presented of a proposed trial of Hirulog versus heparin after thrombolytic therapy with streptokinase (SK). The lower patency rates achieved with SK compared with tissue plasminogen activator (t‐PA) suggest that a potent thrombin specific agent may be more important for SK than for t‐PA therapy. This study will involve more than 400 patients with two dose levels of Hirulog. Endpoints will be angiographic patency, and ST segment monitoring showing evidence of coronary reperfusion.